{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,18]],"date-time":"2026-10-18T02:30:37Z","timestamp":1792290637791,"version":"4.4.0"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.fr","clinicalkey.com.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.bpobgyn.2017.09.007","type":"journal-article","created":{"date-parts":[[2017,9,28]],"date-time":"2017-09-28T23:00:12Z","timestamp":1506639612000},"page":"48-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Medical therapy for fibroids: An overview"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2058-722X","authenticated-orcid":false,"given":"Vikram","family":"Sinai Talaulikar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bpobgyn.2017.09.007_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/01.AOG.0000154161.03418.e3","article-title":"Age-specific incidence rates for self-reported uterine leiomyomata in the Black Women's health study","volume":"105","author":"Wise","year":"2005","journal-title":"Obstet Gynecol"},{"issue":"2","key":"10.1016\/j.bpobgyn.2017.09.007_bib2","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.ejogrb.2012.07.023","article-title":"Progesterone and progesterone receptor modulators in the management of symptomatic uterine fibroids","volume":"165","author":"Talaulikar","year":"2012","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib3","first-page":"20","article-title":"Estradiol and progesterone binding in uterine leiomyomata and in normal uterine tissue","volume":"55","author":"Wilson","year":"1980","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib4","doi-asserted-by":"crossref","first-page":"307","DOI":"10.3109\/00016348509155136","article-title":"Comparison of cellular levels of steroid receptors in uterine leiomyomas and myometrium","volume":"64","author":"Tamaya","year":"1985","journal-title":"Acta Gynaecol Scand"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib5","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2217\/WHE.13.28","article-title":"Efficacy and safety of oral tranexamic acid in women with heavy menstrual bleeding and fibroids","volume":"9","author":"Eder","year":"2013","journal-title":"Women\u2019s Health (Lond, Engl)"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib6","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.05.015","article-title":"A\u00a0dose-response study of a novel, oral tranexamic formulation for heavy menstrual bleeding","volume":"205","author":"Freeman","year":"2011","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib7","doi-asserted-by":"crossref","first-page":"275","DOI":"10.2165\/00002018-200831040-00001","article-title":"A\u00a0benefit-risk review of systemic haemostatic agents: Part 2: in excessive or heavy menstrual bleeding","volume":"31","author":"Fraser","year":"2008","journal-title":"Drug Saf"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib8","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1111\/j.1600-0412.2012.01361.x","article-title":"Efficacy of tranexamic acid in the treatment of idiopathic and non-functional heavy menstrual bleeding: a systematic review","volume":"91","author":"Naoulou","year":"2012","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"2","key":"10.1016\/j.bpobgyn.2017.09.007_bib9","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1002\/ijgo.12047","article-title":"A\u00a0systematic review and meta-analysis of the effect of prophylactic tranexamic acid treatment in major benign uterine surgery","volume":"136","author":"Topsoee","year":"2017","journal-title":"Int J Gynaecol Obstet"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib10","article-title":"Non-steroidal anti-inflammatory drugs for heavy menstrual bleeding","volume":"1","author":"Lethaby","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"1","key":"10.1016\/j.bpobgyn.2017.09.007_bib11","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.maturitas.2014.06.002","article-title":"EMAS position statement: management of uterine fibroids","volume":"79","author":"P\u00e9rez-L\u00f3pez","year":"2014","journal-title":"Maturitas"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib12","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00404-013-2797-9","article-title":"Oral contraceptive use and uterine leiomyomarisk: a meta-analysis based on cohort and case\u2013control studies","volume":"288","author":"Qin","year":"2013","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib13","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1517\/14656566.2013.825607","article-title":"Therapeutic drugs in the treat-ment of symptomatic uterine fibroids","volume":"14","author":"Hoellen","year":"2013","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib14","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1080\/01443610400009543","article-title":"Medical management of uterine fibroids with medroxyprogesterone acetate (Depo Provera): a pilot study","volume":"24","author":"Venkatachalam","year":"2004","journal-title":"J\u00a0Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib15","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s00404-010-1732-6","article-title":"Beneficial effects of dienogest on uterine myoma volume: a retrospective controlled study comparing study comparing with gonadotropin-releasing hormone agonist","volume":"284","author":"Ichigo","year":"2011","journal-title":"Arch Gynecol Obstet"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib16","article-title":"Progestogensor progestogen-releasing intrauterine systems for uterine fibroids","volume":"2","author":"Sangkomkamhang","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib17","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1097\/00004347-198609000-00005","article-title":"Endometrial morphology during long term use of levonorgestrel releasing intrauterine devices","volume":"5","author":"Silverberg","year":"1986","journal-title":"Int J Gynaecol Pathol"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib18","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/j.1471-0528.1998.tb10172.x","article-title":"Randomised comparative trial of the levonorgestrel intrauterine system and norethisterone for treatment of idiopathic menorrhagia","volume":"105","author":"Irvine","year":"1998","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib19","doi-asserted-by":"crossref","first-page":"480","DOI":"10.3109\/13625187.2011.614028","article-title":"Levonorgestrel releasing-intrauterine system for the treatment of menorrhagia and\/or frequent irregular uterine bleeding associated with uterine leiomyoma","volume":"16","author":"Socolov","year":"2011","journal-title":"Eur J Contracept Reprod Health Care"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib20","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.ejogrb.2010.08.017","article-title":"A\u00a060-month non-comparative study on bleeding profiles with the levonorgestrel intrauterine system from the late transition period to estrogen supplemented menopause","volume":"153","author":"Depypere","year":"2010","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib21","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ijgo.2011.07.031","article-title":"Efficacy of the levonorgestrel-releasing intrauterine system in uterine leiomyoma","volume":"116","author":"Kriplani","year":"2012","journal-title":"Int J Gynaecol Obstet"},{"issue":"2","key":"10.1016\/j.bpobgyn.2017.09.007_bib22","doi-asserted-by":"crossref","first-page":"224","DOI":"10.12891\/ceog1826.2015","article-title":"Levonorgestrel-releasing intrauterine device use as an alternative to surgical therapy for uterine leiomyoma","volume":"42","author":"Senol","year":"2015","journal-title":"Clin Exp Obstet Gynecol"},{"issue":"10\u201311","key":"10.1016\/j.bpobgyn.2017.09.007_bib23","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/S0039-128X(00)00171-9","article-title":"Effects of progesterone on uterine leiomyoma growth and apoptosis","volume":"65","author":"Maruo","year":"2000","journal-title":"Steroids"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib24","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.steroids.2014.05.002","article-title":"Levonorgestrel-releasing intrauterine system use in premenopausal women with symptomatic uterine leiomyoma: a systematic review","volume":"86","author":"Jiang","year":"2014","journal-title":"Steroids"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib25","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.fertnstert.2009.05.070","article-title":"GnRH analogue treatment before hysteroscopic resection of submucous myomas: a prospective, randomized, multicenter study","volume":"94","author":"Muzii","year":"2010","journal-title":"Fertil Steril"},{"issue":"2","key":"10.1016\/j.bpobgyn.2017.09.007_bib26","article-title":"Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids","author":"Lethaby","year":"2001","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.bpobgyn.2017.09.007_bib27","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1007\/s13224-012-0206-0","article-title":"GnRH agonists: do they have a place in the modern management of fibroid disease?","volume":"62","author":"Sinai Talaulikar","year":"2012","journal-title":"J\u00a0Obstet Gynaecol India"},{"issue":"10","key":"10.1016\/j.bpobgyn.2017.09.007_bib28","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1111\/j.1471-0528.2002.01225.x","article-title":"Efficacy of pre-operative gonadotrophin hormone releasing analogues for women with uterine fibroids under-going hysterectomy or myomectomy: a systematic review","volume":"109","author":"Lethaby","year":"2002","journal-title":"BJOG"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib29","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/j.bpobgyn.2007.07.010","article-title":"An evidence-based approach to hormonal therapies for premenopausal women with fibroids","volume":"22","author":"Lethaby","year":"2008","journal-title":"Best Pract Res Clin Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2017.09.007_bib30","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.fertnstert.2007.11.006","article-title":"Action of aromatase inhibitor for treatment of uterine leiomyoma in perimenopausal patients","volume":"91","author":"Hil\u00e1rio","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib31","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.ejogrb.2015.06.018","article-title":"Three-month treatment with triptorelin, letrozole and ulipristal acetate before hysteroscopic resection of uterine myomas: prospective comparative pilot study","volume":"192","author":"Bizzarri","year":"2015","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib32","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ejogrb.2014.07.040","article-title":"Preoperative treatment with letrozole in patients undergoing laparoscopic myomectomy of large uterine myomas: a prospective non-randomized study","volume":"181","author":"Leone Roberti Maggiore","year":"2014","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"1","key":"10.1016\/j.bpobgyn.2017.09.007_bib33","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.fertnstert.2008.09.064","article-title":"A\u00a0randomized, controlled clinical trial comparing the effects of aromatase inhibitor (letrozole) and gonadotropin-releasing hormone agonist (triptorelin) on uterine leiomyoma volume and hormonal status","volume":"93","author":"Parsanezhad","year":"2010","journal-title":"Fertil Steril"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib34","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/S0015-0282(02)04761-1","article-title":"Successful treatment of a symptomatic uterine leiomyoma in a perimenopausal woman with a nonsteroidal aromatase inhibitor","volume":"79","author":"Shozu","year":"2003","journal-title":"Fertil Steril"},{"issue":"10","key":"10.1016\/j.bpobgyn.2017.09.007_bib35","article-title":"Aromatase inhibitors for uterine fibroids","author":"Song","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib36","article-title":"Selective estrogen receptor modulators (SERMs) for uterine leiomyomas","volume":"10","author":"Deng","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.bpobgyn.2017.09.007_bib37","article-title":"Herbal preparations for uterine fibroids","volume":"4","author":"Liu","year":"2013","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Best Practice & Research Clinical Obstetrics & Gynaecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693417301402?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521693417301402?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,8,3]],"date-time":"2022-08-03T13:26:58Z","timestamp":1659533218000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521693417301402"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":37,"alternative-id":["S1521693417301402"],"URL":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2017.09.007","relation":{},"ISSN":["1521-6934"],"issn-type":[{"value":"1521-6934","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Medical therapy for fibroids: An overview","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Obstetrics & Gynaecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bpobgyn.2017.09.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}